The Gateway to Better Health
We are committed to bringing effective medicines with distinct safety and dosing advantages to underserved patients by using the gut as the gateway to better health.Learn About Us
We are committed to scientific and clinical integrity with a passionate pursuit of medical innovation to deliver the highest-quality therapeutics to improve the lives of underserved patients impacted by GI and cardiorenal diseases.
Our pipeline of gut-restricted therapies is concentrated on providing better medicines in two therapeutic areas: GI and cardiorenal diseases.
745,000 ESRD patients with hyperphosphatemia in major developed countries
~2 Million people in U.S. with CKD and/or heart failure have hyperkalemia
~11 Million people in the U.S. with IBS-C
Making Better Medicine For Patients In Need
We have created a unique discovery platform that mimics key aspects of the human GI tract, enabling us to develop exceptional product candidates in a rapid and cost efficient manner.Our Approach To Better Medicine
Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
Tenapanor Represents First Small Molecule, Non-Binder Treatment to Demonstrate Statistically Significant Effect in Hyperphosphatemia. Tenapanor Exhibits Favorable Tolerability Profile; Company Plans to Initiate Second Phase 3Trial, Company to Host Conference…
Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia
“The Phase 3 study for hyperkalemia marks the start of the fifth Phase 3 clinical trial from our pipeline of internally developed, gut-restricted treatments in development,” said Mike Raab, chief…
Ardelyx Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference
Ardelyx is focused on enhancing the care and well-being of underserved patients with gastrointestinal (GI) and cardiorenal diseases by using the gut as the gateway to developing high-quality therapeutics. The…